Mesothelin-targeted thorium conjugate has been investigated in MSLN-positive ovarian cancer models, with significant anti-tumor activity seen when MSLN-TTC was used in single-dose regimens in cell line-derived xenografts and single- and multiple-dose regimens in patient-derived xenografts (56). The gene discussed is MSLN; the disease is neoplasm.